Gland and Hormone Related Diseases

All Conditions

Neoplasms

Thyroid Diseases

Thyroid Neoplasms

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

All Drugs and Chemicals

Hormones

Euthyroid Group: Subjects received rhTSH to prepare for radioiodine therapy.

Hypothyroid Group: Thyroid hormone treatment was withheld before radioiodine therapy.

Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.

Euthyroid Group

Paul W Ladenson, MD

The purpose of this study is to determine \[for patients with previously treated well-differentiated thyroid cancer and evidence of residual disease based on serum thyroglobulin (Tg) level\] whether positron emission tomography-computed tomography (PET-CT) fusion scanning performed after recombinant thyroid-stimulating hormone (TSH) (rTSH, thyrotropin alfa for injection) will be more sensitive for the detection of disease sites than PET-CT scanning without rTSH. The study will also determine if this information will significantly alter the therapeutic approach in some patients.

PET/CT was performed before (basal PET) and 24 - 48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.

Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer

Utility of Recombinant Human Thyrotropin (rTSH) PET-CT Fusion Scanning to Identify Residual Well-differentiated Epithelial Thyroid Cancer

PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET.

Gustave Roussy, Cancer Campus, Grand Paris

M.D. Anderson Cancer Center

Genzyme, a Sanofi Company

Johns Hopkins University

Adults (age \>18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.

Subjects received rhTSH to prepare for radioiodine therapy

Adults (age \>18 years) with a history of treated well-differentiated epithelial thyroid carcinoma (papillary, follicular, or Hürthle cell), for which total or near total thyroidectomy plus postoperative radioiodine remnant ablation with 131-I has either been performed or found to be unnecessary by radioiodine imaging after TSH stimulation.

Thyroid hormone treatment was withheld before radioiodine therapy.

Hypothyroid Group

Total

Age, Categorical

Sex: Female, Male

France

United States

Region of Enrollment

Paul W. Ladenson, MD, Professor and PI

Subjects received rhTSH to prepare for radioiodine therapy.

Thyroid hormone treatment was withheld before radioiodine therapy.

PET-CT Fusion Scanning Sensitivity

Increased Fluorodeoxyglucose (FDG) PET Standardized Uptake Value (SUV) After rTSH Specificity

Subjects received rhTSH to prepare for radioiodine therapy

Spots Global Cancer Trial Database for recombinant thyrotropin